Yuan Xia, Zhang Jing, Li Dan, Mao Ye, Mo Fei, Du Wei, Ma Xuelei
State Key Laboratory of Biotherapy and Cancer Center, West China Hospital, West China Medical School Sichuan University, Chengdu, PR China.
West China Medical School Sichuan University, Chengdu, PR China.
Gynecol Oncol. 2017 Oct;147(1):181-187. doi: 10.1016/j.ygyno.2017.07.007. Epub 2017 Jul 8.
The role of tumor-associated macrophages (TAMs) in tumor microenvironment remains controversial due to the two different polarized subsets of TAMs. Here, we performed a meta-analysis to evaluate the correlation between subpopulations of TAMs and clinical outcomes in patients with ovarian cancer.
A comprehensive search in PUBMED/Medline and EMBASE databases was performed. The association between TAMs and patient prognosis of ovarian cancer was estimated with hazard ratios (HRs) and their corresponding 95% confidence intervals (95% CIs) using a random-effect model. Additionally, sensitivity analysis and Begg's test were conducted.
Nine studies including 794 patients were enrolled in the meta-analysis. The results showed that higher M1/M2 ratio in tumor tissues was associated with a favorable overall survival (OS) (HR=0.449, 95% CI=0.283-0.712, P=0.001). Elevated intra-islet M1/M2 TAMs ratio showed a positive correlation for OS (HR=0.510, 95% CI=0.264-0.986, P=0.045). No significant relation was observed between OS and CD68+ TAMs (HR=0.99, 95% CI=0.88-1.11, P=0.859), CD163+ TAMs (HR=1.04, 95% CI=0.92-1.16, P=0.544) or CD163+/CD68+ TAMs ratio (HR=1.628, 95% CI=0.529-5.008, P=0.395). Worse progression-free survival (PFS) was associated with high density of CD163+ TAMs (HR=2.157, 95% CI=1.406-3.312, P=0.000) and higher ratio of CD163+/CD68+ TAMs (HR=3.223, 95% CI=1.805-5.755, P=0.000). Elevated M1/M2 TAMs ratio predicted better PFS of ovarian cancer (HR=0.490, 95% CI=0.270-0.890, P=0.019). Furthermore, high density of CD163+ and CD68+ TAMs was observed in ovarian cancer with advanced TNM stage.
In our study, it was revealed that CD163+ TAMs infiltration was associated with poor prognosis of ovarian cancer and high M1/M2 macrophages ratio in tumor tissues predicted better prognosis.
由于肿瘤相关巨噬细胞(TAM)存在两种不同的极化亚群,其在肿瘤微环境中的作用仍存在争议。在此,我们进行了一项荟萃分析,以评估TAM亚群与卵巢癌患者临床结局之间的相关性。
对PUBMED/Medline和EMBASE数据库进行全面检索。使用随机效应模型,通过风险比(HR)及其相应的95%置信区间(95%CI)评估TAM与卵巢癌患者预后之间的关联。此外,还进行了敏感性分析和Begg检验。
9项研究共纳入794例患者进行荟萃分析。结果显示,肿瘤组织中较高的M1/M2比值与较好的总生存期(OS)相关(HR=0.449,95%CI=0.283-0.712,P=0.001)。胰岛内M1/M2 TAM比值升高与OS呈正相关(HR=0.510,95%CI=0.264-0.986,P=0.045)。未观察到OS与CD68+ TAM(HR=0.99,95%CI=0.88-1.11,P=0.859)、CD163+ TAM(HR=1.04,95%CI=0.92-1.16,P=0.544)或CD163+/CD68+ TAM比值(HR=1.628,95%CI=0.529-5.008,P=0.395)之间存在显著关联。无进展生存期(PFS)较差与CD163+ TAM的高密度(HR=2.157,95%CI=1.406-3.312,P=0.000)以及较高的CD163+/CD68+ TAM比值(HR=3.223,95%CI=1.805-5.755,P=0.000)相关。升高的M1/M2 TAM比值预示着卵巢癌患者的PFS较好(HR=0.490,95%CI=0.270-0.890,P=0.019)。此外,在TNM分期较晚的卵巢癌中观察到CD163+和CD68+ TAM的高密度。
在我们的研究中,揭示了CD163+ TAM浸润与卵巢癌预后不良相关,肿瘤组织中较高的M1/M2巨噬细胞比值预示着较好的预后。